174 related articles for article (PubMed ID: 1384801)
21. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma.
Newton DL; Hansen HJ; Mikulski SM; Goldenberg DM; Rybak SM
Blood; 2001 Jan; 97(2):528-35. PubMed ID: 11154233
[TBL] [Abstract][Full Text] [Related]
22. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
Van Horssen PJ; Preijers FW; Van Oosterhout YV; De Witte T
Int J Cancer; 1996 Nov; 68(3):378-83. PubMed ID: 8903481
[TBL] [Abstract][Full Text] [Related]
23. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
Conry RM; Khazaeli MB; Saleh MN; Ghetie V; Vitetta ES; Liu T; LoBuglio AF
J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):231-41. PubMed ID: 8680651
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
26. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
Uckun FM; Manivel C; Arthur D; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Gunther R
Blood; 1992 May; 79(9):2201-14. PubMed ID: 1373967
[TBL] [Abstract][Full Text] [Related]
27. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice.
Flavell DJ; Noss A; Pulford KA; Ling N; Flavell SU
Cancer Res; 1997 Nov; 57(21):4824-9. PubMed ID: 9354445
[TBL] [Abstract][Full Text] [Related]
28. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
29. Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells.
van Horssen PJ; van Oosterhout YV; Evers S; Backus HH; van Oijen MG; Bongaerts R; de Witte T; Preijers FW
Leukemia; 1999 Feb; 13(2):241-9. PubMed ID: 10025898
[TBL] [Abstract][Full Text] [Related]
30. Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies.
Mansfield E; Pastan I; FitzGerald DJ
Bioconjug Chem; 1996; 7(5):557-63. PubMed ID: 8889017
[TBL] [Abstract][Full Text] [Related]
31. Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains.
Ghetie V; Swindell E; Uhr JW; Vitetta ES
J Immunol Methods; 1993 Nov; 166(1):117-22. PubMed ID: 8228282
[TBL] [Abstract][Full Text] [Related]
32. B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic leukemia cells.
Bregni M; Siena S; Formosa A; Lappi DA; Martineau D; Malavasi F; Dorken B; Bonadonna G; Gianni AM
Blood; 1989 Feb; 73(3):753-62. PubMed ID: 2465042
[TBL] [Abstract][Full Text] [Related]
33. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
Stone MJ; Sausville EA; Fay JW; Headlee D; Collins RH; Figg WD; Stetler-Stevenson M; Jain V; Jaffe ES; Solomon D; Lush RM; Senderowicz A; Ghetie V; Schindler J; Uhr JW; Vitetta ES
Blood; 1996 Aug; 88(4):1188-97. PubMed ID: 8695836
[TBL] [Abstract][Full Text] [Related]
34. The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond.
Ghetie V; Thorpe P; Ghetie MA; Knowles P; Uhr JW; Vitetta ES
J Immunol Methods; 1991 Sep; 142(2):223-30. PubMed ID: 1717600
[TBL] [Abstract][Full Text] [Related]
35. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
Senderowicz AM; Vitetta E; Headlee D; Ghetie V; Uhr JW; Figg WD; Lush RM; Stetler-Stevenson M; Kershaw G; Kingma DW; Jaffe ES; Sausville EA
Ann Intern Med; 1997 Jun; 126(11):882-5. PubMed ID: 9163289
[No Abstract] [Full Text] [Related]
36. Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.
Barta SK; Zou Y; Schindler J; Shenoy N; Bhagat TD; Steidl U; Verma A
Leuk Lymphoma; 2012 Oct; 53(10):1999-2003. PubMed ID: 22448921
[TBL] [Abstract][Full Text] [Related]
37. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
[TBL] [Abstract][Full Text] [Related]
38. Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines.
Stanciu-Herrera C; Morgan C; Herrera L
Leuk Res; 2008 Apr; 32(4):625-32. PubMed ID: 17706771
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins.
Winkler U; Gottstein C; Schön G; Kapp U; Wolf J; Hansmann ML; Bohlen H; Thorpe P; Diehl V; Engert A
Blood; 1994 Jan; 83(2):466-75. PubMed ID: 8286745
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
